Sugi Predict

Sugi Predict / Compounds / SCHEMBL5504385

SCHEMBL5504385

SCHEMBL5504385

O=Cc1nc(-c2ccccc2)c(-c2ccccc2)o1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 15/20 0.64
▸ RXRA P19793 9/20 0.64
▸ RXRB P28702 9/20 0.64
▸ NR4A1 P22736 3/20 0.64
▸ NR4A3 Q92570 3/20 0.64
▸ RXRG P48443 6/20 0.60
▸ KDM4E B2RXH2 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ PTGS2 P35354 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ ABCC4 O15439 1/20 0.47
▸ C5 P01031 1/20 0.47
▸ CHRM2 P08172 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ DRD2 P14416 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ TBXA2R P21731 1/20 0.47
▸ PTGS1 P23219 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27879778 0.87 NR4A2 (0.52) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL27896715 0.82 NR4A2 (0.55) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL11450560 0.82 NR4A2 (0.65) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL7486524 0.81 NR4A2 (0.59) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL28597233 0.81 NR4A2 (0.46) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL28591071 0.79 ALDH1A1 (0.50) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL5733581 0.78 NR4A2 (1.00) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL13754893 0.78 NR4A2 (0.74) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL4467013 0.76 MAPK14 (0.58) PTGS2PTGS1MAPK13MAPK12MAPK11
SCHEMBL4477244 0.76 MAPK14 (0.58) PTGS2PTGS1MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3318561-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2021-12-22 — — EP disclosed
EP-3318561-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2021-12-22 — — EP disclosed
US-10562916-B2 Substituted quinoxalines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS, INC. (US) 2020-02-18 — — US disclosed
US-10562916-B2 Substituted quinoxalines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS, INC. (US) 2020-02-18 — — US disclosed
EP-2576540-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2019-09-04 — — EP disclosed
EP-2576540-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2019-09-04 — — EP disclosed
EP-3318561-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2018-05-09 — — EP disclosed
EP-3318561-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2018-05-09 — — EP disclosed
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS SUNOVION PHARMACEUTICALS INC. 2018-02-08 — — US disclosed
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS SUNOVION PHARMACEUTICALS INC. 2018-02-08 — — US disclosed
US-7256296-B2 Heterocycle-amine ligands, compositions, complexes, and catalysts SYMYX TECHNOLOGIES, INC. (US) 2007-08-14 — — US disclosed
EP-1794196-A2 HETEROCYCLE-AMINE LIGANDS, COMPOSITIONS, COMPLEXES, AND CATALYSTS, AND METHODS OF MAKING AND USING THE SAME Symyx Technologies, Inc. (US) 2007-06-13 — — EP disclosed
WO-2006036748-A2 HETEROCYCLE-AMINE LIGANDS, COMPOSITIONS, COMPLEXES, AND CATALYSTS, AND METHODS OF MAKING AND USING THE SAME SYMYX TECHNOLOGIES, INC. (US) 2006-04-06 — — WO disclosed
EP-0842161-B1 4,5-DIARYL OXAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2002-09-18 — — EP disclosed
EP-1213285-A2 4,5-dipheny-oxazole derivatives and their use as platelet aggregation inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-06-12 — — EP disclosed
US-6300344-B1 FOR THERAPEUTIC AND/OR PROPHYLACTIC TREATMENT OF ARTERIAL OBSTRUCTION, CEREBROVASCULAR DISEASE, HEPATIC CIRRHOSIS, ARTERIOSCLEROSIS, ISCHEMIC HEART DISEASE, RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, HYPERTENSION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-09 — — US disclosed
US-5972965-A USEFUL FOR INHIBITION OF PLATELET AGGREGATION, VASODILATION, ANTIHYPERTENSIVE ACTIVITY AND PROSTAGLANDIN AGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-26 — — US disclosed
EP-0842161-A1 4,5-DIARYL OXAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-05-20 — — EP disclosed
WO-1997003973-A1 4,5-DIARYL OXAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-02-06 — — WO disclosed
CN-1115576-A Oxazolinone derivative having intracellular phospholipase A2 inhibitor activity SHIONOGI & CO (JP) 1996-01-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS PDE10A, PDE2A, PDE3A NR4A2 2780/4885RXRA 961/4885RXRB 1169/4885
US-10562916-B2 Substituted quinoxalines as PDE-10 inhibitors PDE4A, PDE2A, PDE9A NR4A2 2265/4885RXRA 2290/4885RXRB 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.